Meeder Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Meeder Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-156	Closed	-$3K	–	2688
2021 Q2	$3K	Buy	+156	New	+$3.09K	﹤0.01%	2148
2020 Q2	–	Sell	-104	Closed	-$7K	–	2584
2020 Q1	$7K	Buy	104 +89	+593%	+$8K	﹤0.01%	1678
2019 Q4	$2K	Buy	+15	New	+$1.34K	﹤0.01%	2078
2019 Q3	–	Sell	-76	Closed	-$6K	–	2298
2019 Q2	$6K	Sell	76 -151	-67%	-$13.5K	﹤0.01%	1633
2019 Q1	$25K	Buy	227 +92	+68%	+$10.1K	﹤0.01%	1031
2018 Q4	$14K	Buy	+135	New	+$14K	﹤0.01%	1163
2017 Q2	–	Sell	-46	Closed	-$5K	–	1935
2017 Q1	$5K	Buy	+46	New	+$5.37K	﹤0.01%	1109

Other funds holding ICPT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EAM

EULAV Asset Management Sarasota, Florida $3.12B AUM 13.38% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meeder Asset Management's ICPT Position: Q3 2021 in Review

Meeder Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2021, closing a stake of 156 shares — an estimated $3K sold.

Meeder Asset Management first reported a position in ICPT in Q1 2017 and held it in 7 quarters. The position peaked at $25K in Q1 2019. 139 funds tracked by Wall St. Rank hold ICPT as of Q3 2021.

Meeder Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Meeder Asset Management sold 156 Intercept Pharmaceuticals, Inc. shares in Q3 2021, an estimated $3K.
Meeder Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2017 and held it in 7 quarters.
Meeder Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $25K in Q1 2019.
139 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2021.

Based on Meeder Asset Management's 13F filing for Q3 2021, filed 8 Nov 2021.